Objective: To review the efficacy and safety of infliximab (IFX) in the treatment of intravenous immunoglobulin (IVIG) resistant Kawasaki disease ( KD). Methods: PubMed

the Cochrane Library

Medline

CNKI

Wanfang Database and Chinese Biological Medical Literature Databases were searched by computer

and the articles about IFX in the treatment of IVIG-resistant KD from the establishment of each database to June 2020 were collected. Meta-analysis was performed on the articles that met the inclusion criteria using Review Manager 5. 3. Results: A total of 5 articles were included

which was divided into IFX treatment group (81 cases) and re-IVIG treatment control group (211 cases). The results of Meta-analysis showed that the antipyretic rate in the IFX treatment group was significantly higher than that in the control group after the first IVIG treatment (RR=1. 38

95%CI 1. 20-1. 59

P<0. 01)

but there was no significant difference in the incidence of coronary artery lesions (CALs) and adverse events between the two groups (P>0. 05). Conclusion: At present

the evidence shows that after the first IVIG treatment

IFX treatment can control body temperature more effectively than IVIG treatment in children with IVIG resistant KD

but there is no significant difference in the incidence of CALs and adverse events between the two groups.